PAK1 and leukemia: Residual leukemia cells after cytarabine treatment develop a PI3Kγ dependency. Eganelisib selectively inhibits PI3Kγ, thereby phosphorylating the atypical substrate PAK1, which impacts mitochondrial oxidative phosphorylation and overcomes chemotherapy resistance in leukemia cells